Accendra Health: a new CEO can't fix a $1.7 billion debt load

Accendra Health expects to name a new chief executive by mid-September, and the prospect reads like a fresh start for a beaten-down stock. The company once known as Owens & Minor trades for about a dollar a share after an 80% collapse over the past year. New leadership, go. But the transition is happening at a company whose shareholders sit under roughly $1.7 billion of net debt, and the business underneath that debt is shrinking and losing cash. Before reading the CEO change as a turnaround signal, the reader should see what the new executive is actually inheriting.

The reinvention that left the leverage behind

Accendra Health is the remnant of a big restructuring. In late 2025, Owens & Minor sold its far larger Products & Healthcare Services business to Platinum Equity for about $375 million in cash and renamed the remaining company Accendra Health, trading on the New York Stock Exchange as ACH starting in January 2026. What stayed behind is the home-based care operation built around the Apria and Byram brands — the home-health business CEO Ed Pesicka had spent years reshaping.

The spin-off refocused the company, but it did not make it solvent. At the end of the second quarter, Accendra carried about $1.71 billion in net debt against roughly $82 million of stock-market value. A $1.79 billion enterprise value that is almost entirely borrowed money means the equity is a small tail on a very large debt dog. On a book basis the company's shareholders' equity is negative, which is a direct way of saying the company owes more than the value of what it owns.

That capital structure, not the leadership transition, is what has driven the stock's fall. From a 52-week high of $5.62, the shares are down more than 60% year to date. This is worth spelling out: the multiple did not reset faster than the business deteriorated. It reset because the balance sheet has been the last thing an equity holder can claim against.

The operating business is shrinking, not just priced down

A cheap valuation at the debt level is not the same as a cheap stock at the equity level, and the second-quarter numbers show why the collapse is justified rather than overdone. Revenue for the quarter was $613 million, down about 10% from a year earlier. Adjusted EBITDA fell to $60 million from $96.6 million — a drop of roughly 38%. The company used $25 million of cash in the quarter, and reported an adjusted loss of 19 cents a share.

Some of this is deliberate. Accendra exited a large commercial payor relationship, eliminating more than $125 million of annualized operating expenses, and it cut its full-year guidance to $300–320 million of adjusted EBITDA from the $335–355 million it had guided to in February. Free cash flow for the year is now expected to be roughly breakeven at best. So the strategic housecleaning is real, but the trajectory right now is a smaller business generating less profit and no cash — exactly the profile that makes a heavily levered equity fragile.

The CEO handover is a balance-sheet story disguised as a leadership story. Pesicka, who said in August he would retire by the end of the year, is staying through the transition and then in an advisory role; the board said in mid-August it expected to name his successor by mid-September. But a fresh chief executive does not alter the two facts that matter most here: the company is roughly breakeven on cash while carrying $1.7 billion of debt, and interest on that debt is a claim that sits ahead of every shareholder.

What would make the cheap stock a real opportunity

Cheap is only an edge if the problem is temporary fear rather than a genuine restructuring. In Accendra's case the test is whether the home-health business can stop shrinking, start generating cash, and let debt fall faster than the business declines. Management points to a nationwide rollout of a "Sleep Center of Excellence" and new commercial agreements, but those are expected to help only from late 2026 and into 2027 — a promise, not yet revenue.

The honest read is that this is a high-risk recovery position, not a mispriced growth stock, and the lines matter. A company can be a decent home-healthcare business while its equity is a bad bet, because the creditors own the upside first. The equity recovery is real only if free cash flow turns positive and stays positive and deleveraging outpaces the shrinkage — a proof the company has not yet delivered and that a CEO change does not supply on its own.

For an investor deciding whether the news matters, the practical question is whether the balance sheet, not the name behind the desk, is improving. Watch whether the next quarters show revenue stabilizing, cash turning positive, and net debt trending down. Until the operating business converts to cash, the 80% discount reflects an impaired equity in a levered capital stack — not a mispricing that a signature on a press release can fix.